The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| OTLK | -72.58% | -98.86% | -59.11% | -100% |
| S&P | +17.45% | +75.43% | +11.88% | +225% |
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | -$1,207.83K | 0.0% |
| Gross Profit | -$1,267.53K | -4301.0% |
| Gross Margin | 68.83% | 0.0% |
| Market Cap | $70.18M | 49.1% |
| Market Cap / Employee | $3.05M | 0.0% |
| Employees | 23 | 0.0% |
| Net Income | -$23,058.14K | -232.7% |
| EBITDA | -$13,453.88K | 37.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $8.68M | 52.2% |
| Accounts Receivable | $114.61K | 0.0% |
| Inventory | 3.5 | 11.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $171.99K | -26.2% |
| Short Term Debt | $36.72M | 19.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -125.04% | 80.4% |
| Return On Invested Capital | -78.15% | 225.8% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$14,939.11K | -36.2% |
| Operating Free Cash Flow | -$14,939.11K | -36.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -0.62 | -0.60 | -1.62 | -1.85 | 23.67% |
| Price to Sales | 39.28 | - | |||
| Price to Tangible Book Value | -0.62 | -0.60 | -1.62 | -1.85 | 23.67% |
| Enterprise Value to EBITDA | -3.30 | -5.13 | -5.40 | -9.17 | 47.03% |
| Total Debt | $31.03M | $33.32M | $34.70M | $36.89M | 24.06% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
